INZY (inozyme.com) Forward P/S Multiple

Inozyme Pharma, Inc. (INZY) is implementing robotic molecule screening and software-based data processing for clinical tests. The projected P/S ratio reflects market dynamics, with the current metric recorded at . The business foundation relies on orphan drug status, which guarantees pricing power, as well as high levels of trust from patient communities in the fight against rare metabolic bone pathologies.

Inozyme Pharma Inc. - INZY Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for inozyme.com (INZY)

- market price and analyst price targets:

Price Chart Inozyme Pharma|INZY - Forecast Levels Chart

- business market valuation indicators:

Market Capitalization Inozyme Pharma, Inc.|INZY - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Inozyme Pharma|INZY - Book Capitalization|Market Value to Book Value Ratio inozyme.com|INZY - Aggregate Asset Value

- debt and solvency information:

- financial results and valuation multiples details:

INZY - Company Net Income|Future Profit Inozyme Pharma, Inc.|INZY - Market Cap to Net Income|Projected Price to Earnings Inozyme Pharma|INZY - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma, Inc.|INZY - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Inozyme Pharma|INZY - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months inozyme.com|INZY - Earnings per share increase in current year|Net earnings per share growth forecast for next year Inozyme Pharma, Inc.

- total revenue and sales volume data:

INZY - Company Annual Revenue|Projected Sales Volume Inozyme Pharma|INZY - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Inozyme Pharma, Inc.

Fundamental company analysis:Inozyme INZY

The forward P/S ratio relates the current market value of Inozyme Pharma, Inc. (INZY) to its projected annual revenue, determining the premium investors are willing to pay per unit of future sales. For a biopharmaceutical developer of treatments for rare genetic pathologies, the forward P/S trend reflects market expectations regarding the commercialization of R&D projects, where inflated values signal a high cost of technological leadership and risks of correction.

Analysis of competing companies

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Future Price to Revenue|Insmed Inc - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics Inc.)|BMRN: Forward P/S Multiple|bridgebio.com (BBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio BGM Group Limited|COGT: Forward Price to Sales|Price-to-Projected Revenue Ratio Xeris Biopharma Inc (XERS)|Forward Price-to-Revenue Multiple Keros Corp KROS|Forward P/S Multiple ARCT (Arcturus Therapeutics)|Forward P/S Multiple etonpharma.com ETON|Kamada - Forward P/S Multiple|Market Cap to Expected Sales Ratio Fulcrum Therapeutics Inc FULC|abeonatherapeutics.com (ABEO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MREO|Price-to-Projected Revenue Ratio Protalix BioTherapeutics|Market Cap to Future Revenue Ratio Pliant Rx PLRX|Forward Price-to-Revenue Multiple APLT (Applied Therapeutics, Inc.)|RNTX: Future Price to Revenue|Gelteq - Forward Price-to-Revenue Multiple|Aytu BioPharma Inc (AYTU) - Market Cap to Future Revenue Ratio|CMMB - Price-to-Projected Revenue Ratio|SRx Health Solutions Inc. (SRXH) - Forward Price-to-Revenue Multiple|PLRZ: Forward P/S Multiple|Market Cap to Future Revenue Ratio Aeterna Zentaris Inc. (AEZS)|Forward Price-to-Revenue Multiple CYTH|RPHM: Forward Price to Sales|Price-to-Projected Revenue Ratio COSCIENS Biopharma Inc. (CSCI)